JP2003525207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003525207A5 JP2003525207A5 JP2000621366A JP2000621366A JP2003525207A5 JP 2003525207 A5 JP2003525207 A5 JP 2003525207A5 JP 2000621366 A JP2000621366 A JP 2000621366A JP 2000621366 A JP2000621366 A JP 2000621366A JP 2003525207 A5 JP2003525207 A5 JP 2003525207A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- medicament
- treating
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 19
- 239000003814 drug Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical compound O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 description 3
- -1 4-isobutyl-pyrrolidin-3-yl Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- UKTMYUZOEFEYNX-UHFFFAOYSA-N 4-(2h-tetrazol-5-yl)-2-azaspiro[4.5]decane Chemical compound N=1N=NNC=1C1CNCC21CCCCC2 UKTMYUZOEFEYNX-UHFFFAOYSA-N 0.000 description 1
- DQYXECHFBDDSEZ-HTQZYQBOSA-N 5-[(3s,4s)-4-(2-methylpropyl)pyrrolidin-3-yl]-2h-tetrazole Chemical compound CC(C)C[C@@H]1CNC[C@H]1C1=NN=NN1 DQYXECHFBDDSEZ-HTQZYQBOSA-N 0.000 description 1
- DQYXECHFBDDSEZ-UHFFFAOYSA-N 5-[4-(2-methylpropyl)pyrrolidin-3-yl]-2h-tetrazole Chemical compound CC(C)CC1CNCC1C1=NN=NN1 DQYXECHFBDDSEZ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 0 CC1(*)C(*)CNC1 Chemical compound CC1(*)C(*)CNC1 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- STCPSJQRNFVLNL-UHFFFAOYSA-N OC1ON=CN1 Chemical compound OC1ON=CN1 STCPSJQRNFVLNL-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13709699P | 1999-06-02 | 1999-06-02 | |
| US60/137,096 | 1999-06-02 | ||
| PCT/US2000/011399 WO2000073300A1 (en) | 1999-06-02 | 2000-04-28 | Amino heterocycles useful as pharmaceutical agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003525207A JP2003525207A (ja) | 2003-08-26 |
| JP2003525207A5 true JP2003525207A5 (enExample) | 2007-06-28 |
Family
ID=22475823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000621366A Pending JP2003525207A (ja) | 1999-06-02 | 2000-04-28 | 薬剤として有用なアミノ複素環 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6436974B1 (enExample) |
| EP (1) | EP1187832B1 (enExample) |
| JP (1) | JP2003525207A (enExample) |
| AT (1) | ATE228128T1 (enExample) |
| AU (1) | AU4673300A (enExample) |
| BR (1) | BR0011236A (enExample) |
| CA (1) | CA2371395A1 (enExample) |
| DE (1) | DE60000833T2 (enExample) |
| DK (1) | DK1187832T3 (enExample) |
| ES (1) | ES2185591T3 (enExample) |
| PT (1) | PT1187832E (enExample) |
| WO (1) | WO2000073300A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| ATE390133T1 (de) * | 2000-06-26 | 2008-04-15 | Warner Lambert Co | Gabapentinanaloga für schlafstörungen |
| US6855735B2 (en) * | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
| US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| WO2006034089A1 (en) * | 2004-09-20 | 2006-03-30 | Targacept, Inc. | Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity |
| GB0514686D0 (en) * | 2005-07-18 | 2005-08-24 | Novartis Ag | Organic compounds |
| EP1820502A1 (en) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| AU2014364644A1 (en) | 2013-12-17 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and Sigma receptor ligands combinations |
| AU2014364647A1 (en) | 2013-12-17 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations |
| TW201607923A (zh) * | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1354554A (en) * | 1970-08-31 | 1974-06-05 | Robins Co Inc A H | 2-substituted benzimidazoles |
| EP0402056A3 (en) * | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| US5066662A (en) * | 1990-05-21 | 1991-11-19 | Warner-Lambert Company | Substituted oxazolidin-2-ones and 1,2,4-oxadiazolin-5-ones and derivatives thereof acting at muscarinic receptors |
| HU9301648D0 (en) * | 1990-12-05 | 1993-09-28 | Synphar Lab Inc | Substituted oxaquinoline-3-carboxylic acids of bactericidal effect and method for producing them |
| US5342846A (en) * | 1990-12-05 | 1994-08-30 | Synphar Laboratories, Inc. | 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents |
| US5356902A (en) | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
| US5446051A (en) * | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
| US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
-
2000
- 2000-04-28 CA CA002371395A patent/CA2371395A1/en not_active Abandoned
- 2000-04-28 DE DE60000833T patent/DE60000833T2/de not_active Expired - Fee Related
- 2000-04-28 EP EP00928499A patent/EP1187832B1/en not_active Expired - Lifetime
- 2000-04-28 DK DK00928499T patent/DK1187832T3/da active
- 2000-04-28 JP JP2000621366A patent/JP2003525207A/ja active Pending
- 2000-04-28 ES ES00928499T patent/ES2185591T3/es not_active Expired - Lifetime
- 2000-04-28 PT PT00928499T patent/PT1187832E/pt unknown
- 2000-04-28 AU AU46733/00A patent/AU4673300A/en not_active Abandoned
- 2000-04-28 BR BR0011236-4A patent/BR0011236A/pt not_active IP Right Cessation
- 2000-04-28 AT AT00928499T patent/ATE228128T1/de not_active IP Right Cessation
- 2000-04-28 US US09/980,187 patent/US6436974B1/en not_active Expired - Fee Related
- 2000-04-28 WO PCT/US2000/011399 patent/WO2000073300A1/en not_active Ceased